4,871 results on '"Braunwald, Eugene"'
Search Results
152. Angiographic Outcomes With Early Eptifibatide Therapy in Non–ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial)
153. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
154. Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel: An Analysis From the TRITON–TIMI 38 Study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38)
155. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial
156. Cell-Based Therapy in Cardiac Regeneration: An Overview
157. Response by Bohula et al to Letters Regarding Article, “Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)”
158. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis
159. André Cournand, Bellevueʼs Cardiopulmonary Laboratory, and Research on Heart Failure
160. Aortic Stenosis: A 6-Decade Odyssey.
161. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
162. Abstract 17950: High-Dose Edoxaban Regimen versus Warfarin in Patients With Atrial Fibrillation and Established Coronary Artery Disease: Insights From the ENGAGE AF-TIMI 48 Trial
163. Abstract 17307: Biomarkers, Cardiovascular Outcomes and Effect of Ezetimibe After Acute Coronary Syndrome in the IMPROVE-IT Trial
164. Abstract 17194: High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure and a Preserved Ejection Fraction - Insights From the Heart Failure Network
165. Abstract 16613: Serial High-Sensitivity Troponin T and Cardiovascular Outcomes in Patients in the IMPROVE-IT Trial
166. Abstract 15480: The Efficacy and Safety of More Potent Antiplatelet Therapy With Vorapaxar in Patients With Impaired Renal Function: Insights From the TRA 2P-TIMI 50 Trial
167. Abstract 15134: Comparison of Events Across Definitions of Major Bleeding in the Engage AF-TIMI 48 Trial
168. Abstract 11709: Klotho, Fibroblast Growth Factor-23, and the Renin-Angiotensin System - An Analysis From the PEACE Trial
169. A tribute to Donald W. Seldin
170. Control of residual dyslipidaemic risk
171. Cardiac Xenotransplantation
172. Cardiac xenotransplantation: a new path for the treatment of advanced heart failure?
173. Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present
174. Gliflozins in the Management of Cardiovascular Disease
175. Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?—Reply
176. Changing the Trajectory of Heart Failure and Kidney Disease
177. Reading: Keeping Current
178. Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes
179. Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2–TIMI 51)
180. Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51
181. Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non–ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends
182. The Spectrum of Myocardial Ischemia : The Paradigm of Acute Coronary Syndromes
183. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients with Acute Myocardial Infarction:Insights from the PARADISE-MI Trial
184. An Important Step for Thrombocardiology
185. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
186. Cardiomyopathies: An Overview
187. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48)
188. Obesity and the Response to Intensified Diuretic Treatment in Decompensated Heart Failure: A DOSE Trial Substudy
189. The Spectrum of Myocardial Ischemia : The Paradigm of Acute Coronary Syndromes
190. Association Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome) Angiographic Substudy
191. Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research Network
192. Cardiac cell therapy: a call for action
193. Leaders in cardiovascular research: Eugene Braunwald
194. SERIAL ASSESSMENT OF BIOMARKERS AND THE RISK OF HEART FAILURE IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ENGAGE AF-TIMI 48 TRIAL
195. NEUTROPHIL-LYMPHOCYTE RATIO AND OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION: ANALYSES FROM ENGAGE AF-TIMI 48 TRIAL
196. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis
197. ASSESSMENT OF ATHEROTHROMBOTIC RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
198. Heart failure: a 70 year Odyssey
199. Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT
200. Reply
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.